Top Page
ASP Isotopes, Inc.
(NASDAQ:ASPI)
ASP Isotopes, Inc. (ASPI) vs. SPDR S&P 500 ETF (SPY)
ASP Isotopes, Inc. Business Overview & Revenue Model
ASP Isotopes, Inc. Earnings Call Summary
ASP Isotopes, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.38M | 4.14M | 433.03K | 0.00 | 0.00 |
| Gross Profit | 1.93M | 1.60M | 138.97K | -72.57K | -19.38K |
| EBITDA | -106.65M | -31.58M | -16.14M | -4.87M | -2.59M |
| Net Income | -105.56M | -32.33M | -16.29M | -4.79M | -2.61M |
Balance Sheet | |||||
| Total Assets | 225.89M | 94.35M | 30.19M | 12.50M | 7.14M |
| Cash, Cash Equivalents and Short-Term Investments | 113.94M | 61.89M | 7.91M | 2.39M | 2.95M |
| Total Debt | 113.66M | 37.75M | 2.14M | 822.20K | 926.60K |
| Total Liabilities | 129.29M | 43.18M | 11.36M | 2.68M | 1.14M |
| Stockholders Equity | 74.07M | 47.90M | 16.30M | 9.82M | 6.00M |
Cash Flow | |||||
| Free Cash Flow | -33.96M | -28.07M | -7.74M | -7.41M | -3.57M |
| Operating Cash Flow | -23.69M | -16.70M | -5.41M | -2.94M | -577.69K |
| Investing Cash Flow | -38.63M | -11.37M | -2.45M | -4.47M | -2.99M |
| Financing Cash Flow | 125.15M | 82.53M | 13.39M | 6.64M | 6.50M |
ASP Isotopes, Inc. Technical Analysis
ASP Isotopes, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
58 Neutral | $668.36M | -876.42 | -0.13% | ― | 12.49% | 95.48% | |
58 Neutral | $425.53M | 8.24 | 6.62% | 3.81% | -5.05% | 35.01% | |
56 Neutral | $519.96M | -1.25 | -78.11% | ― | -9.75% | -386.63% | |
49 Neutral | $793.20M | -4.45 | -187.23% | ― | 147.78% | -137.42% | |
49 Neutral | $960.83M | -2.96 | -18.65% | 8.27% | -7.81% | -334.15% | |
47 Neutral | $1.37B | -1.57 | ― | ― | -10.68% | 36.31% |
ASP Isotopes, Inc. Corporate Events
On January 26, 2026, ASP Isotopes Inc. agreed to invest in biotechnology company Opeongo, Inc. by purchasing 4,356,918 shares of Opeongo’s Series Seed-1 preferred stock at $2.2952 per share, gaining a significant equity stake in a business developing extracellular matrix-modulating therapeutics targeting fibrosis, inflammation and cancer. As part of the deal, ASP Isotopes secured conversion, voting, anti-dilution and veto rights, the ability for preferred holders to elect a dedicated board director, and a commitment to negotiate a supply agreement giving it a right of first offer on medical isotope supply for any future Opeongo pharmaceutical products, while related-party executives Paul Mann and Todd Wider took on board roles under new governance, rights and transfer-restriction arrangements that deepen ASP Isotopes’ strategic alignment with Opeongo and expand its potential role in the biotech value chain.
The most recent analyst rating on (ASPI) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on ASP Isotopes, Inc. stock, see the ASPI Stock Forecast page.
On January 7, 2026, ASP Isotopes announced new leadership appointments tied to the January 6, 2026 closing of its acquisition of Renergen Limited, naming Renergen CEO and co-founder Stefano Marani as President, Electronics and Space, and Renergen COO Nick Mitchell as Co-Chief Operating Officer. The company outlined compensation packages for both executives, including base salaries of $550,000 for Marani and $400,000 for Mitchell, performance-based annual bonuses partly payable in stock, and inducement grants of 700,000 restricted shares each that will vest in eight equal installments over four years, reinforcing their long-term alignment with ASP Isotopes. These appointments bring extensive structured finance, operational and gas-industry expertise into ASP Isotopes as it integrates Renergen and its Virginia Gas Project, while also formalizing equity-based incentives and indemnification arrangements that underscore the strategic importance and financial interdependence of the two businesses, including prior bridge financing and related-party considerations.
The most recent analyst rating on (ASPI) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on ASP Isotopes, Inc. stock, see the ASPI Stock Forecast page.
On January 6, 2026, ASP Isotopes Inc. completed its previously announced all-stock acquisition of South Africa-based Renergen Limited, a producer of liquefied helium and liquefied natural gas, via a court-approved scheme of arrangement under South African company law. ASP Isotopes acquired all issued Renergen ordinary shares in exchange for ASP Isotopes common stock at a 0.09196-for-1 exchange ratio, issuing roughly 14.27 million new shares, with Renergen becoming a direct, wholly owned subsidiary and its shares delisted from the Johannesburg Stock Exchange, the Australian Securities Exchange and A2X, while ASP Isotopes’ stock remains listed on Nasdaq and the JSE; the deal also brings Renergen’s senior executives into key leadership roles at ASP Isotopes, underscoring a strategic move to integrate helium and LNG assets and expertise into its portfolio and potentially broaden its role in electronics and space-related markets.
The most recent analyst rating on (ASPI) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on ASP Isotopes, Inc. stock, see the ASPI Stock Forecast page.
ASP Isotopes Inc. held its 2025 Annual Meeting of Stockholders on December 18, 2025, at which shareholders addressed director elections and the appointment of the company’s external auditor. At the meeting, stockholders re-elected two Class III directors, Sipho N. Maseko and Todd Wider, M.D., to serve until the 2028 annual meeting or until their successors are chosen, and ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, reinforcing continuity in both board leadership and financial oversight for the company and its investors.
The most recent analyst rating on (ASPI) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on ASP Isotopes, Inc. stock, see the ASPI Stock Forecast page.
On December 18, 2025, ASP Isotopes Inc. confirmed that South Africa’s Takeover Regulation Panel had issued a compliance certificate for its scheme of arrangement to acquire all issued ordinary shares of Renergen Limited, under which Renergen shareholders would receive 0.09196 new ASP Isotopes shares for each Renergen share, allowing the transaction to proceed toward implementation. The timetable sets out key milestones through mid‑January 2026, including suspension and eventual termination of Renergen’s listings on the JSE, A2X and ASX, the listing and settlement of new ASP Isotopes shares to former Renergen shareholders in South Africa and Australia, and the handling of fractional cash entitlements, underscoring the complexity of the cross‑border settlement structure and marking a significant step in ASP Isotopes’ expansion via the full acquisition and delisting of Renergen.
The most recent analyst rating on (ASPI) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on ASP Isotopes, Inc. stock, see the ASPI Stock Forecast page.
ASP Isotopes Inc. announced that effective January 19, 2026, Paul Mann, the founder and Executive Chairman, will resume his role as Chief Executive Officer while continuing as Executive Chairman. Robert Ainscow, who served as Interim CEO during Mann’s medical leave, will remain as Chief Operating Officer. The company has not made any new contractual arrangements related to Mann’s re-appointment.
The most recent analyst rating on (ASPI) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on ASP Isotopes, Inc. stock, see the ASPI Stock Forecast page.
On November 7, 2025, Quantum Leap Energy LLC, a subsidiary of ASP Isotopes Inc., announced a Convertible Note Purchase Agreement to issue and sell $64.3 million in convertible promissory notes to accredited investors. The proceeds will be used to develop laser enrichment production facilities and for general corporate purposes. The offering, expected to close around November 17 or 18, 2025, will also see the automatic conversion of existing 2024 Convertible Notes into new 2025 Notes. This move positions QLE to enhance its operational capabilities and potentially impact its market standing.
The most recent analyst rating on (ASPI) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on ASP Isotopes, Inc. stock, see the ASPI Stock Forecast page.